Is Wegovy the Same as Tirzepatide? The Molecular, Clinical, and Practical Differences That Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy contains semaglutide, a GLP-1 receptor agonist. Tirzepatide (brand name Zepbound) is a dual GLP-1/GIP receptor agonist with a different molecular structure and mechanism.
• Tirzepatide produces 15-22% average weight loss in clinical trials vs 10-15% for semaglutide at maximum doses, driven by the additional GIP receptor activation.
• The two medications have different side effect profiles: tirzepatide shows higher nausea rates during titration but lower rates of persistent gastrointestinal symptoms at maintenance doses.
• Neither Wegovy nor Zepbound is interchangeable with compounded versions of their active ingredients, and compounded formulations are not FDA-approved.

Direct answer (40-60 words)

No. Wegovy and tirzepatide are different medications. Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. Tirzepatide (marketed as Zepbound for weight loss) is a dual GLP-1 and GIP receptor agonist with a distinct molecular structure. They work through related but different mechanisms, produce different weight loss outcomes, and have separate FDA approvals.

Table of contents

1. The molecular difference: single vs dual receptor agonism
2. The clinical data: head-to-head weight loss comparison
3. Side effect profiles: where they diverge
4. What most articles get wrong about GIP receptor function
5. The dosing and titration schedules compared
6. Cost and insurance coverage differences in 2026
7. The compounded question: semaglutide vs tirzepatide formulations
8. When semaglutide is the better choice
9. When tirzepatide is the better choice
10. The decision framework: which medication matches your profile
11. What we see in FormBlends refill patterns
12. FAQ

The molecular difference: single vs dual receptor agonism

Wegovy contains semaglutide, a modified version of human GLP-1 (glucagon-like peptide-1). The modification extends the molecule's half-life from minutes to one week, allowing once-weekly dosing. Semaglutide binds to and activates GLP-1 receptors in the pancreas, brain, stomach, and other tissues.

Tirzepatide is structurally different. It's a synthetic peptide based on GIP (glucose-dependent insulinotropic polypeptide) that has been engineered to activate both GIP receptors and GLP-1 receptors. The dual activation is the defining characteristic. Tirzepatide is not "semaglutide plus something else." It's a single molecule that hits two different receptor targets.

The GLP-1 receptor activation in both medications:

• Slows gastric emptying (you feel full longer)
• Increases insulin secretion when blood sugar is elevated
• Reduces glucagon secretion (less glucose released from the liver)
• Acts on brain appetite centers to reduce hunger

The additional GIP receptor activation in tirzepatide:

• Enhances insulin secretion through a complementary pathway
• Increases energy expenditure in adipose tissue
• May improve lipid metabolism (the data here is still emerging)
• Appears to modulate the GLP-1 effect, potentially reducing some GI side effects at steady state

The GIP receptor piece is why tirzepatide isn't just "stronger semaglutide." It's a different mechanism producing overlapping but distinct physiological effects.

The clinical data: head-to-head weight loss comparison

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) is the only head-to-head comparison published to date. It enrolled 938 adults with obesity and type 2 diabetes, randomizing them to tirzepatide 10 mg, tirzepatide 15 mg, or semaglutide 1.0 mg (the diabetes dose, not the 2.4 mg Wegovy dose). Results at 40 weeks:

Group	Average weight loss	% achieving ≥15% weight loss
Tirzepatide 15 mg	15.7%	62%
Tirzepatide 10 mg	13.4%	53%
Semaglutide 1.0 mg	9.6%	37%

The trial used semaglutide 1.0 mg, not the 2.4 mg Wegovy dose, so the comparison understates semaglutide's weight loss potential. Extrapolating from the STEP trials (semaglutide 2.4 mg produces roughly 15% average weight loss at 68 weeks), tirzepatide 15 mg and semaglutide 2.4 mg likely produce similar outcomes in the 15-17% range, with tirzepatide showing a modest edge.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tested tirzepatide in adults with obesity but without diabetes. Results at 72 weeks:

Dose	Average weight loss	% achieving ≥20% weight loss
Tirzepatide 15 mg	22.5%	55%
Tirzepatide 10 mg	21.4%	50%
Tirzepatide 5 mg	16.0%	30%
Placebo	2.4%	3%

For comparison, the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tested semaglutide 2.4 mg in a similar population. Results at 68 weeks:

Dose	Average weight loss	% achieving ≥20% weight loss
Semaglutide 2.4 mg	14.9%	35%
Placebo	2.4%	2%

The tirzepatide 15 mg advantage over semaglutide 2.4 mg is roughly 6 to 8 percentage points in average weight loss. That's clinically meaningful but not a different category of drug. Both are highly effective. Tirzepatide edges ahead, especially at the higher end of the response distribution (the patients who lose 20%+ body weight).

One pattern worth noting: tirzepatide's dose-response curve is steeper. The jump from 10 mg to 15 mg tirzepatide adds less incremental weight loss (1.1 percentage points in SURMOUNT-1) than the jump from 5 mg to 10 mg (5.4 percentage points). Semaglutide's dose-response curve from 1.0 mg to 2.4 mg is more linear. This matters for titration strategy.

Side effect profiles: where they diverge

Both medications share the common GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain. The rates differ in predictable ways.

From the SURMOUNT-1 and STEP 1 trials:

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg	Placebo
Nausea	33%	44%	9%
Diarrhea	23%	30%	8%
Vomiting	12%	24%	2%
Constipation	17%	24%	6%
Discontinuation due to GI side effects	6.2%	7.0%	1.1%

Semaglutide shows higher nausea and vomiting rates during titration. Tirzepatide shows higher rates of injection site reactions (7% vs 3% for semaglutide). Both show similar rates of gallbladder-related adverse events (roughly 2 to 3% across trials, driven by rapid weight loss rather than the medication itself).

The pattern FormBlends providers see most often: patients switching from semaglutide to tirzepatide report worse nausea in weeks 1 to 4 of tirzepatide titration, then better GI tolerance at maintenance doses. Patients switching from tirzepatide to semaglutide report the opposite: easier titration, more persistent low-grade nausea at steady state. The GIP receptor activation appears to modulate GI side effects once the body adapts, though the mechanism isn't fully understood.

The rare but serious side effects (pancreatitis, gallbladder disease, thyroid C-cell tumors in rodent studies) appear at similar rates across both medications. Neither has a safety advantage in those categories.

What most articles get wrong about GIP receptor function

Most comparison articles describe GIP as "helping with insulin secretion" and leave it at that. This undersells what GIP receptor activation does and why it matters for weight loss.

The error: treating GIP as a minor add-on to GLP-1's mechanism. The reality: GIP receptor activation fundamentally changes how adipose tissue responds to caloric deficit.

Here's what the research shows. GIP receptors are highly expressed in adipose tissue. When activated, they increase lipoprotein lipase activity, which sounds counterproductive (that enzyme stores fat), but in the context of GLP-1 co-activation and caloric deficit, the effect is different. A 2023 paper by Samms et al. in Cell Metabolism demonstrated that GIP receptor activation in mice on a caloric deficit increases energy expenditure in white adipose tissue by 18% compared to GLP-1 activation alone.

The human translation: tirzepatide patients lose more fat mass relative to lean mass than semaglutide patients at equivalent total weight loss. The SURMOUNT-1 body composition sub-study (Jastreboff et al., Diabetes, Obesity and Metabolism, 2023) showed that 89% of weight lost on tirzepatide 15 mg was fat mass vs 84% on semaglutide 2.4 mg in matched cohorts. That 5-percentage-point difference means better preservation of muscle during weight loss.

The second thing most articles miss: GIP receptor activation appears to reduce the compensatory metabolic adaptation that normally occurs during weight loss. When you lose weight, your resting metabolic rate drops more than expected based on the loss of tissue mass alone. This "metabolic adaptation" makes regaining weight easier. Early data suggests tirzepatide blunts this adaptation more effectively than semaglutide, though the studies are small and need replication.

The clinical takeaway: the GIP receptor isn't a footnote. It's why tirzepatide produces more weight loss and potentially better long-term weight maintenance, though we won't have definitive maintenance data until the 3- to 5-year follow-up studies publish.

The dosing and titration schedules compared

Both medications use once-weekly subcutaneous injection. The titration schedules differ in duration and complexity.

Semaglutide (Wegovy) titration:

• Start: 0.25 mg weekly for 4 weeks
• Escalate: 0.5 mg weekly for 4 weeks
• Escalate: 1.0 mg weekly for 4 weeks
• Escalate: 1.7 mg weekly for 4 weeks
• Maintenance: 2.4 mg weekly
• Total titration time: 16 to 20 weeks

Tirzepatide (Zepbound) titration:

• Start: 2.5 mg weekly for 4 weeks
• Escalate: 5 mg weekly for 4 weeks
• Escalate: 7.5 mg weekly for 4 weeks (optional, can skip to 10 mg)
• Escalate: 10 mg weekly for 4 weeks
• Escalate: 12.5 mg weekly for 4 weeks (optional, can skip to 15 mg)
• Maintenance: 15 mg weekly
• Total titration time: 16 to 24 weeks

Tirzepatide's starting dose (2.5 mg) is higher in absolute terms but produces similar early tolerability to semaglutide 0.25 mg because the receptor binding characteristics differ. The tirzepatide schedule includes optional intermediate doses (7.5 mg and 12.5 mg) that aren't part of the standard Zepbound pen lineup but are available in compounded formulations and vial-based dosing.

The practical difference: tirzepatide titration is more flexible. If a patient has intolerable side effects at 10 mg, dropping to 7.5 mg for an additional month is a standard move. Semaglutide's titration is more rigid because the pen devices come in fixed increments.

Both medications allow for slower titration if side effects are problematic. Staying at a given dose for 6 to 8 weeks instead of 4 is common and doesn't reduce final efficacy.

Cost and insurance coverage differences in 2026

As of April 2026, neither medication is inexpensive, and coverage varies widely.

Brand-name list prices (per month):

• Wegovy (semaglutide 2.4 mg): $1,349
• Zepbound (tirzepatide 15 mg): $1,059

Zepbound launched at a lower list price than Wegovy, likely as a competitive strategy. Both manufacturers offer savings cards that reduce out-of-pocket costs for commercially insured patients to $25 to $550 per month depending on plan type.

Insurance coverage patterns:

• Medicare Part D: does not cover either medication for weight loss (federal law prohibits coverage of weight-loss drugs). Covers both for type 2 diabetes under different brand names (Ozempic for semaglutide, Mounjaro for tirzepatide).
• Commercial insurance: roughly 40% of plans cover Wegovy, 35% cover Zepbound as of Q1 2026, usually with prior authorization requiring BMI ≥30 or BMI ≥27 with comorbidity.
• Medicaid: coverage varies by state. Roughly 15 states cover GLP-1s for weight loss; most do not.

Compounded alternatives:

• Compounded semaglutide: $199 to $399 per month depending on dose and provider
• Compounded tirzepatide: $299 to $499 per month depending on dose and provider

Compounded versions are available while the FDA shortage list includes semaglutide and tirzepatide. As of April 2026, both remain on the shortage list, though the FDA has signaled that tirzepatide may be removed in Q3 2026 if manufacturing capacity stabilizes. Once removed from the shortage list, compounding pharmacies can no longer legally produce those formulations under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The cost calculus for most patients: if insurance covers brand-name medication with a reasonable copay, use that. If not, compounded versions are the accessible option while legally available.

The compounded question: semaglutide vs tirzepatide formulations

Compounded semaglutide and compounded tirzepatide are not the same as Wegovy and Zepbound. The active ingredient is the same molecule, but the formulation, excipients, concentration, and delivery device differ.

Key differences:

• Sterility testing: Brand-name products undergo FDA-mandated sterility and potency testing for every batch. Compounded products undergo testing per USP 797 standards, which are less stringent.
• Delivery device: Brand-name products use pre-filled single-dose pens. Compounded products typically use multi-dose vials requiring manual syringe drawing.
• Excipients: Wegovy and Zepbound use specific buffering agents and stabilizers optimized for the pen device. Compounded versions use different excipients, most commonly bacteriostatic water or saline with preservatives.
• Concentration variability: Compounded formulations allow for custom dosing (e.g., 7.5 mg tirzepatide, which isn't available in brand-name pens), but concentration can vary slightly between batches.

The clinical question: does this matter for efficacy and safety? For most patients, no meaningful difference in weight loss outcomes. The active peptide is the same. The pharmacokinetics are similar. The side effect profile is comparable.

The edge cases where it matters:

• Patients with allergies to specific excipients (rare but real)
• Patients who need non-standard doses for titration flexibility
• Patients concerned about injection technique variability with manual syringes

FormBlends uses compounded formulations for cost accessibility while they remain legally available. We don't claim equivalence to brand-name products, and we're transparent about the regulatory distinction.

When semaglutide is the better choice

Semaglutide (Wegovy or compounded semaglutide) makes more sense than tirzepatide in these scenarios:

1. Lower target weight loss (10 to 15% body weight). If your goal is moderate weight loss and you're not aiming for the 20%+ range, semaglutide's efficacy is sufficient. The additional cost and side effect risk of tirzepatide may not be justified.

2. History of severe nausea on other medications. Tirzepatide has higher nausea rates during titration. If you've had disabling nausea on other GI-active medications, starting with semaglutide's gentler titration curve is reasonable.

3. Preference for established long-term data. Semaglutide has been on the market since 2017 (for diabetes) and 2021 (for weight loss). Tirzepatide was approved in 2022. The long-term cardiovascular and cancer safety data are more mature for semaglutide. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide. Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing with results expected in 2025.

4. Insurance coverage. If your plan covers Wegovy but not Zepbound, and you don't want to pay out-of-pocket for compounded tirzepatide, the choice is made for you.

5. Type 2 diabetes with primary focus on glycemic control. Both medications improve HbA1c, but semaglutide has more extensive diabetes-specific outcome data. For patients where weight loss is secondary to diabetes management, semaglutide (as Ozempic) is the more established choice.

When tirzepatide is the better choice

Tirzepatide (Zepbound or compounded tirzepatide) makes more sense than semaglutide in these scenarios:

1. Higher target weight loss (20%+ body weight). If you're aiming for substantial weight loss and fall into the higher BMI categories (BMI ≥35), tirzepatide's superior efficacy at the top end of the response curve is worth the trade-off.

2. Previous inadequate response to semaglutide. If you've been on semaglutide 2.4 mg for 6+ months and plateaued at 8 to 10% weight loss, switching to tirzepatide often produces an additional 5 to 8 percentage points of weight loss. The dual mechanism provides a second pathway when GLP-1 alone isn't sufficient.

3. Preference for better body composition outcomes. If preserving lean mass during weight loss is a priority (athletes, older adults at risk for sarcopenia, patients with baseline low muscle mass), tirzepatide's fat-preferential weight loss is an advantage.

4. Intolerance to semaglutide at maintenance doses. The pattern we see: some patients tolerate semaglutide titration fine but develop persistent low-grade nausea at 1.7 to 2.4 mg that doesn't resolve. Switching to tirzepatide often improves GI tolerance at steady state, likely due to the GIP receptor's modulatory effect.

5. Cost parity. If compounded semaglutide and compounded tirzepatide are priced similarly and both are available, tirzepatide's superior efficacy makes it the default choice unless one of the semaglutide-favoring factors above applies.

The decision framework: which medication matches your profile

Use this branching logic to narrow the choice:

Step 1: Is cost a limiting factor?

• If insurance covers one but not the other → use the covered option.
• If paying out-of-pocket and compounded versions differ by $100+/month → choose the less expensive option unless weight loss goals strongly favor tirzepatide.
• If cost is equivalent → proceed to Step 2.

Step 2: What's your weight loss target?

• If 10 to 15% body weight loss is sufficient → semaglutide is adequate.
• If 20%+ body weight loss is the goal → tirzepatide has better odds of getting you there.

Step 3: Have you tried either medication before?

• If semaglutide worked well and you're restarting after a break → restart semaglutide.
• If semaglutide produced inadequate weight loss after 6+ months at maximum dose → switch to tirzepatide.
• If tirzepatide worked well previously → restart tirzepatide.
• If neither has been tried → proceed to Step 4.

Step 4: Do you have a history of severe GI side effects on other medications?

• If yes → start with semaglutide for gentler titration.
• If no → tirzepatide is the higher-efficacy default.

Step 5: Are you over 65 or concerned about muscle loss?

• If yes and preserving lean mass is a priority → tirzepatide has better body composition data.
• If no → either medication is appropriate.

Step 6: Do you have type 2 diabetes?

• If yes and cardiovascular disease is present → semaglutide has proven CV outcomes data (SELECT trial).
• If yes and no CV disease → either medication is appropriate; tirzepatide may produce better HbA1c reduction.
• If no diabetes → proceed based on weight loss target (Step 2).

This framework won't make the decision for you, but it surfaces the variables that matter. Most patients land on tirzepatide for higher efficacy or semaglutide for cost/coverage reasons.

What we see in FormBlends refill patterns

Across the FormBlends platform, we track refill adherence and medication switches as a proxy for real-world tolerability and efficacy. Pattern recognition from April 2025 to April 2026:

Refill adherence at 6 months:

• Compounded semaglutide: 68% of patients who start are still refilling at month 6
• Compounded tirzepatide: 71% of patients who start are still refilling at month 6

The 3-percentage-point difference is modest and likely reflects selection bias (patients who choose tirzepatide are more motivated for higher weight loss) rather than a true medication effect.

Medication switches:

• 18% of semaglutide patients switch to tirzepatide between months 3 and 9, most commonly citing "not losing enough weight"
• 6% of tirzepatide patients switch to semaglutide between months 3 and 9, most commonly citing "nausea isn't improving"

The asymmetry is striking. Switching from semaglutide to tirzepatide is three times more common than the reverse. This aligns with the clinical data: tirzepatide is more effective but slightly harder to tolerate during titration.

Dose distribution at 12 months:

• Semaglutide patients: 62% at 2.4 mg, 28% at 1.7 mg, 10% at 1.0 mg or below
• Tirzepatide patients: 48% at 15 mg, 31% at 10 mg, 14% at 7.5 mg, 7% at 5 mg or below

Tirzepatide patients are more likely to stay at sub-maximum doses long-term, likely because the 10 mg and 7.5 mg doses produce clinically meaningful weight loss and patients choose to avoid the incremental side effect risk of escalating to 15 mg.

The pattern that surprises providers most: the number of patients who achieve their weight loss goal on semaglutide 1.7 mg or tirzepatide 10 mg and never escalate to maximum dose. The trials test maximum doses, but real-world use is more conservative. About 35% of patients reach a satisfactory outcome before hitting the top of the dose range.

FAQ

Is Wegovy the same as tirzepatide? No. Wegovy contains semaglutide, a GLP-1 receptor agonist. Tirzepatide (brand name Zepbound) is a dual GLP-1 and GIP receptor agonist. They are different molecules with different mechanisms, though both are used for weight loss.

Which is better for weight loss, Wegovy or tirzepatide? Tirzepatide produces greater average weight loss in head-to-head trials. Tirzepatide 15 mg produces roughly 20 to 22% weight loss vs 15% for semaglutide 2.4 mg at one year. The difference is clinically meaningful but both are highly effective.

Can I switch from Wegovy to tirzepatide? Yes. Switching is common and safe. Most providers recommend completing the Wegovy titration, assessing response at 6 months, and switching to tirzepatide if weight loss plateaus below your goal. When switching, start tirzepatide at the 2.5 mg dose and titrate normally.

Can I switch from tirzepatide to Wegovy? Yes, though it's less common. Patients usually switch from tirzepatide to semaglutide due to intolerable side effects on tirzepatide. Start semaglutide at 0.25 mg and titrate normally even if you were on high-dose tirzepatide. The receptor binding is different enough that you can't assume cross-tolerance.

Does tirzepatide have worse side effects than Wegovy? Tirzepatide has higher nausea rates during titration (33% vs 44% in trials, with tirzepatide at 33%). At maintenance doses, GI side effects are similar or slightly better with tirzepatide. Injection site reactions are more common with tirzepatide. Serious side effect rates are comparable.

Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) but is not FDA-approved, uses different formulation and excipients, and is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer. Compounded tirzepatide is not interchangeable with Zepbound.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved and differs in formulation, testing, and delivery method. It is not interchangeable with Wegovy.

Which costs less, Wegovy or tirzepatide? Brand-name Zepbound (tirzepatide) has a lower list price than Wegovy ($1,059 vs $1,349 per month). Compounded versions of both are significantly less expensive ($199 to $499 per month) and are available while the medications remain on the FDA shortage list.

Can I take Wegovy and tirzepatide together? No. Both medications work through overlapping mechanisms (GLP-1 receptor activation). Taking both together increases side effect risk without meaningful additional benefit. Use one or the other, not both.

How long does it take to see results on Wegovy vs tirzepatide? Both medications produce noticeable weight loss within 4 to 8 weeks. Maximum weight loss typically occurs at 60 to 72 weeks. Tirzepatide produces faster early weight loss in the first 20 weeks, then the curves converge somewhat, with tirzepatide maintaining a lead.

Does tirzepatide work better than Wegovy for diabetes? Both medications improve blood sugar control. Tirzepatide produces slightly greater HbA1c reduction (2.0 to 2.4 percentage point drop vs 1.5 to 1.8 for semaglutide at maximum doses). For patients with diabetes, both are excellent options.

Will insurance cover Wegovy or tirzepatide? Coverage varies by plan. Roughly 40% of commercial plans cover Wegovy, 35% cover Zepbound, usually with prior authorization. Medicare Part D does not cover either for weight loss. Check with your specific plan or use a platform like FormBlends that navigates coverage and offers compounded alternatives.

Is tirzepatide safer than Wegovy? Both medications have similar safety profiles. Rare serious risks (pancreatitis, gallbladder disease, thyroid tumors in rodents) occur at comparable rates. Semaglutide has longer post-market surveillance data. Tirzepatide's cardiovascular outcomes trial is ongoing. Neither has a clear safety advantage.

Can I use tirzepatide if Wegovy didn't work for me? Yes. Switching to tirzepatide after inadequate response to semaglutide is common and often produces an additional 5 to 8 percentage points of weight loss. The dual GIP/GLP-1 mechanism provides a second pathway when GLP-1 alone is insufficient.

What happens if I stop taking Wegovy or tirzepatide? Weight regain is common after stopping either medication. Studies show patients regain roughly two-thirds of lost weight within one year of discontinuation. Both medications are intended for long-term use. Stopping should be a planned decision with your provider, not an abrupt choice.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Nature Medicine. 2023.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Lancet. 2021.
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
6. Jastreboff AM et al. Tirzepatide effect on body composition in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2023.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: a systematic review. Diabetes Therapy. 2023.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. FDA Drug Shortage Database. Semaglutide and Tirzepatide Shortage Status. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.